Completed PHASE3 INTERVENTIONAL 2-arm NCT01919801

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults

Sponsor: PPD Development, LP

Conditions Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Interventions Icatibant Placebo

Updated 12 times since 2017 Last updated: May 14, 2021 Started: Dec 2, 2013 Primary completion: Aug 22, 2015 Completion: Aug 22, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01919801, this PHASE3 trial focuses on Angiotensin Converting Enzyme Inhibitor Induced Angioedema and remains completed. Sponsored by PPD Development, LP, it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Jun 2025 — Sep 2025 [monthly]

Completed PHASE3
Oct 2024 — Jun 2025 [monthly]

Completed PHASE3
Sep 2024 — Oct 2024 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2019 [monthly]

Completed PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PPD Development, LP
Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Baltimore, United States , Beersheba, Israel , Boston, United States , Brighton, United Kingdom , Brooklyn, United States , Chambersburg, United States , Charlottesville, United States , Chicago, United States , Cincinnati, United States and 35 more locations